High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1 blockade.
10.1038/s41591-020-0860-1 Yuen et al. Nat. Med.
Yuen KC, Liu LF, Gupta V, Madireddi S, Keerthivasan S, Li C, Rishipathak D, Williams P, Kadel EE, Koeppen H, Chen YJ, Modrusan Z, Grogan JL, Banchereau R, Leng N, Thastrom A, Shen X, Hashimoto K, Tayama D, van der Heijden MS, Rosenberg JE, McDermott DF, Powles T, Hegde PS, Huseni MA, Mariathasan S
Study details